Conducting Clinical Research in Rare Pulmonary Disorders
APRN Goals
-
Provide a large resource pool of qualified patients for pharmaceutical companies to recruit patients for clinical trials through a single point of contact in the Atlanta area.
- Conduct clinical trials of promising new drugs for the treatment of Pulmonary Hypertension and Interstitial Lung Diseases (ILDs).
- Apply for federally funded/pharmaceutical research grants to support research and development activities of the APRN.
- Provide opportunities for community based investigators to establish research experience in the field of Pulmonary Hypertension/ILD.
- Establish a referral structure for the comprehensive diagnosis of PAH/ILD to assure proper management of patients with these conditions.
- Enroll a large group of patients with Pulmonary Hypertension/Scleroderma into observational studies through the patient registries maintained by the Canadian Heart Institute for the purpose of identifying and evaluating diagnostic and treatment practices of these conditions according to consensus standards.
- Establish a patient contact registry.
- Develop improved methods for studying PAH and ILD.
- Help other scientists do more research on Pulmonary Hypertension by providing specimens and clinical data from the APRN for analysis. (Currently working with Raymond Benza, M.D. at UAB for pharmacogenomics studies on PAH patients funded through the NIH).
- Work with Pulmonary Hypertension and Scleroderma patient support groups to help those patients who wish to be involved in research connect with those doctors conducting the research.
- Construct and maintain an electronic website resource with significant information for clinicians, researchers, and patients.
Site Menu
Resources
